Cargando…
Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion
BACKGROUND: TFAP2D is a transcription factor important for modulating gene expression in embryogenesis. Its expression and prognostic role in prostate cancer has not been evaluated. METHODS: Therefore, a tissue microarray containing 17,747 prostate cancer specimens with associated pathological, clin...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060561/ https://www.ncbi.nlm.nih.gov/pubmed/32143573 http://dx.doi.org/10.1186/s10020-020-00148-4 |
_version_ | 1783504257335427072 |
---|---|
author | Fraune, Christoph Harms, Luisa Büscheck, Franziska Höflmayer, Doris Tsourlakis, Maria Christina Clauditz, Till S. Simon, Ronald Möller, Katharina Luebke, Andreas M. Möller-Koop, Christina Steurer, Stefan Hube-Magg, Claudia Sauter, Guido Weidemann, Sören Lebok, Patrick Dum, David Kind, Simon Minner, Sarah Izbicki, Jakob R. Schlomm, Thorsten Huland, Hartwig Heinzer, Hans Burandt, Eike Haese, Alexander Graefen, Markus Schroeder, Cornelia |
author_facet | Fraune, Christoph Harms, Luisa Büscheck, Franziska Höflmayer, Doris Tsourlakis, Maria Christina Clauditz, Till S. Simon, Ronald Möller, Katharina Luebke, Andreas M. Möller-Koop, Christina Steurer, Stefan Hube-Magg, Claudia Sauter, Guido Weidemann, Sören Lebok, Patrick Dum, David Kind, Simon Minner, Sarah Izbicki, Jakob R. Schlomm, Thorsten Huland, Hartwig Heinzer, Hans Burandt, Eike Haese, Alexander Graefen, Markus Schroeder, Cornelia |
author_sort | Fraune, Christoph |
collection | PubMed |
description | BACKGROUND: TFAP2D is a transcription factor important for modulating gene expression in embryogenesis. Its expression and prognostic role in prostate cancer has not been evaluated. METHODS: Therefore, a tissue microarray containing 17,747 prostate cancer specimens with associated pathological, clinical, and molecular data was analyzed by immunohistochemistry to assess the role of TFAP2D. RESULTS: TFAP2D expression was typically increased in prostate cancer as compared to adjacent non-neoplastic glands. TFAP2D staining was considered negative in 24.3% and positive in 75.7% of 13,545 interpretable cancers. TFAP2D staining was significantly linked to advanced tumor stage, high classical and quantitative Gleason grade, lymph node metastasis, and a positive surgical margin (p ≤ 0.0045). TFAP2D positivity was more common in ERG fusion positive (88.7%) than in ERG negative cancers (66.8%; p < 0.0001). Subset analyses in 3776 cancers with and 4722 cancers without TMPRSS2:ERG fusion revealed that associations with tumor phenotype and patient outcome were largely driven by the subset of ERG negative tumors. Multivariate analysis did not identify TFAP2D protein expression levels as a robust independent prognostic parameter. Positive TFAP2D immunostaining was significantly associated with 10 of 11 previously analyzed chromosomal deletions in ERG negative cancers (p ≤ 0.0244 each) indicating that elevated TFAP2D expression parallels genomic instability in prostate cancer. CONCLUSION: These data demonstrate that TFAP2D protein overexpression is linked to prostate cancer progression and genomic instability in ERG negative prostate cancers. |
format | Online Article Text |
id | pubmed-7060561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70605612020-03-11 Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion Fraune, Christoph Harms, Luisa Büscheck, Franziska Höflmayer, Doris Tsourlakis, Maria Christina Clauditz, Till S. Simon, Ronald Möller, Katharina Luebke, Andreas M. Möller-Koop, Christina Steurer, Stefan Hube-Magg, Claudia Sauter, Guido Weidemann, Sören Lebok, Patrick Dum, David Kind, Simon Minner, Sarah Izbicki, Jakob R. Schlomm, Thorsten Huland, Hartwig Heinzer, Hans Burandt, Eike Haese, Alexander Graefen, Markus Schroeder, Cornelia Mol Med Research Article BACKGROUND: TFAP2D is a transcription factor important for modulating gene expression in embryogenesis. Its expression and prognostic role in prostate cancer has not been evaluated. METHODS: Therefore, a tissue microarray containing 17,747 prostate cancer specimens with associated pathological, clinical, and molecular data was analyzed by immunohistochemistry to assess the role of TFAP2D. RESULTS: TFAP2D expression was typically increased in prostate cancer as compared to adjacent non-neoplastic glands. TFAP2D staining was considered negative in 24.3% and positive in 75.7% of 13,545 interpretable cancers. TFAP2D staining was significantly linked to advanced tumor stage, high classical and quantitative Gleason grade, lymph node metastasis, and a positive surgical margin (p ≤ 0.0045). TFAP2D positivity was more common in ERG fusion positive (88.7%) than in ERG negative cancers (66.8%; p < 0.0001). Subset analyses in 3776 cancers with and 4722 cancers without TMPRSS2:ERG fusion revealed that associations with tumor phenotype and patient outcome were largely driven by the subset of ERG negative tumors. Multivariate analysis did not identify TFAP2D protein expression levels as a robust independent prognostic parameter. Positive TFAP2D immunostaining was significantly associated with 10 of 11 previously analyzed chromosomal deletions in ERG negative cancers (p ≤ 0.0244 each) indicating that elevated TFAP2D expression parallels genomic instability in prostate cancer. CONCLUSION: These data demonstrate that TFAP2D protein overexpression is linked to prostate cancer progression and genomic instability in ERG negative prostate cancers. BioMed Central 2020-03-06 /pmc/articles/PMC7060561/ /pubmed/32143573 http://dx.doi.org/10.1186/s10020-020-00148-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Fraune, Christoph Harms, Luisa Büscheck, Franziska Höflmayer, Doris Tsourlakis, Maria Christina Clauditz, Till S. Simon, Ronald Möller, Katharina Luebke, Andreas M. Möller-Koop, Christina Steurer, Stefan Hube-Magg, Claudia Sauter, Guido Weidemann, Sören Lebok, Patrick Dum, David Kind, Simon Minner, Sarah Izbicki, Jakob R. Schlomm, Thorsten Huland, Hartwig Heinzer, Hans Burandt, Eike Haese, Alexander Graefen, Markus Schroeder, Cornelia Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion |
title | Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion |
title_full | Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion |
title_fullStr | Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion |
title_full_unstemmed | Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion |
title_short | Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion |
title_sort | upregulation of the transcription factor tfap2d is associated with aggressive tumor phenotype in prostate cancer lacking the tmprss2:erg fusion |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060561/ https://www.ncbi.nlm.nih.gov/pubmed/32143573 http://dx.doi.org/10.1186/s10020-020-00148-4 |
work_keys_str_mv | AT fraunechristoph upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT harmsluisa upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT buscheckfranziska upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT hoflmayerdoris upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT tsourlakismariachristina upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT clauditztills upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT simonronald upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT mollerkatharina upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT luebkeandreasm upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT mollerkoopchristina upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT steurerstefan upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT hubemaggclaudia upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT sauterguido upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT weidemannsoren upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT lebokpatrick upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT dumdavid upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT kindsimon upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT minnersarah upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT izbickijakobr upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT schlommthorsten upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT hulandhartwig upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT heinzerhans upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT burandteike upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT haesealexander upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT graefenmarkus upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion AT schroedercornelia upregulationofthetranscriptionfactortfap2disassociatedwithaggressivetumorphenotypeinprostatecancerlackingthetmprss2ergfusion |